177-Lu RAD 204
Alternative Names: 177Lu-RAD-204; Lutetium-177 labelled RAD 204; RAD-204Latest Information Update: 30 Oct 2025
At a glance
- Originator Radiopharm Theranostics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Radioisotopes; Radiopharmaceuticals; Single-domain antibodies
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Solid tumours
Most Recent Events
- 20 Oct 2025 Efficacy and adverse events data from a phase 0 trial in Solid tumours released by (Company)
- 12 May 2025 Data and Safety Monitoring Committee (DSMC)recommends proceeding of RAD 204 in phase I trial for Non small cell lung cancer in Australia
- 22 May 2024 Phase-0 for Solid tumours (Metastatic disease) in Australia (unspecified route) (NCT06305962)